Retatrutide: How a Triple-Acting Peptide Drug Is Performing in Obesity Clinical Trials
Retatrutide, a triple agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously, produced significant weight loss in clinical trials with the 12 mg dose showing the best results across body weight, BMI, and waist circumference.
Quick Facts
What This Study Found
Across three clinical trials screening 1,082 patients (691 randomized: 510 retatrutide, 130 placebo), the 12 mg weekly dose produced the most significant results:
• Greatest reductions in body weight, BMI, and waist circumference across all dose groups
• Higher proportion of patients achieving weight loss thresholds of ≥5%, ≥10%, ≥15%, and ≥20%
• Significant metabolic improvements compared to placebo
• Gastrointestinal adverse effects were the most commonly reported side effects
The study population averaged 54.26 years of age with a near-equal gender split (48% men, 52% women).
Key Numbers
How They Did This
Systematic review following PRISMA guidelines, searching PubMed, Cochrane, and ClinicalTrials.gov from inception through March 15, 2025. Three articles met inclusion criteria, encompassing clinical trials of retatrutide for obesity treatment. Data were extracted on efficacy (weight loss, BMI change, waist circumference) and safety (adverse events) outcomes.
Why This Research Matters
While GLP-1 agonists (semaglutide) and dual agonists (tirzepatide) have already transformed obesity treatment, retatrutide's triple-receptor approach could push weight loss even further. Adding glucagon receptor activation to GLP-1 and GIP signaling may enhance energy expenditure and fat burning beyond what dual agonists achieve, potentially bringing pharmaceutical weight loss closer to bariatric surgery results.
The Bigger Picture
Retatrutide represents the next step in the evolution from single-target GLP-1 agonists (semaglutide) to dual agonists (tirzepatide, targeting GLP-1 + GIP) to triple agonists (GLP-1 + GIP + glucagon). Each generation has produced greater weight loss. Phase 2 data for retatrutide showed weight reductions exceeding 24% at 48 weeks — the highest reported for any anti-obesity medication. This systematic review provides early confirmation of its clinical promise as the drug advances through development.
What This Study Doesn't Tell Us
Only three clinical trials were available for inclusion, limiting the scope of evidence. The total randomized sample (691 patients) is relatively small for a systematic review. Long-term efficacy and safety data beyond the trial periods are not available. The review does not report specific weight loss percentages by dose group. Phase 3 trial results were not yet available at the time of this review.
Questions This Raises
- ?How does retatrutide's weight loss compare directly to semaglutide and tirzepatide in head-to-head trials?
- ?Does the glucagon receptor agonism component of retatrutide improve metabolic outcomes (liver fat, cardiovascular risk) beyond what dual agonists achieve?
- ?What are the long-term safety implications of simultaneously activating three metabolic receptors?
Trust & Context
- Key Stat:
- Triple receptor targeting Retatrutide is the first triple agonist (GLP-1 + GIP + glucagon receptors) in advanced clinical development for obesity, with the 12 mg dose showing the strongest weight loss across all endpoints
- Evidence Grade:
- This is a systematic review of clinical trials following PRISMA guidelines, representing a strong evidence synthesis methodology. However, only three trials were available for inclusion, and the total sample size is modest. The underlying trials appear to be randomized and placebo-controlled, supporting the reliability of the efficacy findings.
- Study Age:
- Published in 2025 with a literature search through March 2025. Retatrutide is still in clinical development, so this review captures early-stage but current evidence. Phase 3 results may substantially update the picture.
- Original Title:
- Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
- Published In:
- Journal of basic and clinical physiology and pharmacology, 36(4), 263-274 (2025)
- Authors:
- Misra, Saurav, Narayan, Ravi Kant, Kaur, Manmeet
- Database ID:
- RPEP-12587
Evidence Hierarchy
Frequently Asked Questions
What makes retatrutide different from semaglutide or tirzepatide?
Semaglutide activates one receptor (GLP-1), tirzepatide activates two (GLP-1 + GIP), and retatrutide activates three (GLP-1 + GIP + glucagon). Each additional receptor adds metabolic effects: GLP-1 reduces appetite, GIP enhances insulin secretion and fat metabolism, and glucagon increases energy expenditure and promotes fat burning. This triple action has produced the largest weight losses seen in any anti-obesity drug trials.
When will retatrutide be available?
As of this 2025 review, retatrutide is still in clinical trials and has not been approved by the FDA. Phase 3 trials are underway and will need to be completed before the manufacturer (Eli Lilly) can apply for approval. If development proceeds normally, approval could potentially come in the next few years.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-12587APA
Misra, Saurav; Narayan, Ravi Kant; Kaur, Manmeet. (2025). Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.. Journal of basic and clinical physiology and pharmacology, 36(4), 263-274. https://doi.org/10.1515/jbcpp-2025-0113
MLA
Misra, Saurav, et al. "Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.." Journal of basic and clinical physiology and pharmacology, 2025. https://doi.org/10.1515/jbcpp-2025-0113
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of retatrutide for the treatment of obes..." RPEP-12587. Retrieved from https://rethinkpeptides.com/research/misra-2025-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.